Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**RNA, 7SL, cytoplasmic 240, pseudogene (RN7SL240P)** is a human **pseudogene** derived from the 7SL RNA gene family[5]. 7SL RNA is an essential component of the **signal recognition particle (SRP)**, which is critical for directing newly synthesized proteins to the endoplasmic reticulum in eukaryotic cells[1]. However, **RN7SL240P** does not code for a functional product; it is a truncated and/or mutant copy of the original 7SL RNA gene that was inserted into the human genome through retrotransposition or related mechanisms and is categorized as a **processed pseudogene**[3]. While some pseudogenes can play regulatory roles—such as acting as non-coding RNA regulators or competitive endogenous RNAs (ceRNAs)—there are no direct reports of RN7SL240P itself having such activity or clinical or therapeutic significance[2][5]. Thus, **RN7SL240P is not considered a therapeutic target, enzyme, receptor, or regulator**.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, 7SL, cytoplasmic 240, pseudogene (RN7SL240P).